[關鍵詞]
[摘要]
目的 探究諾迪康聯(lián)合腦蛋白水解物治療腦梗死患者認知功能障礙的臨床療效.方法 選取2011 年4 月-2014 年4 月平頂山煤業(yè)集團總醫(yī)院收治的腦梗死認知功能障礙的患者80 例,隨機分為對照組和治療組,每組各40 例.對照組在基礎治療上靜脈滴注腦蛋白水解物注射液30 mL+生理鹽水250 mL,1 次/d.治療組在對照組基礎上口服迪諾康膠囊,2 粒/次,3 次/d.兩組均連續(xù)治療30 d.觀察兩組的臨床療效,同時比較兩組患者在治療前后簡易智力狀態(tài)檢查量表(MMSE)評分、日常生活能力調查表(ADL)評分、軀體生活自理量表(PSMS)評分、工具性日常生活能力量表(IADLS)評分的變化.結果 治療后,對照組和治療組的總有效率分別為70.0%、80.0%,兩組比較差異具有統(tǒng)計學意義(P< 0.05).治療后,兩組患者的MMSE 評分均較治療前顯著升高,ADL 評分、PSMS 評分、IDAL 評分均顯著降低,同組治療前后差異有統(tǒng)計學意義(P< 0.05);治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異具有統(tǒng)計學意義(P< 0.05).結論 諾迪康聯(lián)合腦蛋白水解物治療腦梗死認知功能障礙具有較好的臨床療效,可改善患者的智力狀態(tài),提高其生活質量,具有一定的臨床推廣應用價值.
[Key word]
[Abstract]
Objective To investigate the clinical efficacy of Nuodikang Capsules combined with Cerebroprotein Hydrolysate Injection in treatment of cognitive dysfunction after cerebral infarction. Method Patients (80 cases) with cognitive dysfunction after cerebral infarction in Pingdingshan Coal Group General Hospital from April 2011 to April 2014 were randomly divided into control and treatment groups. Each group had 40 cases. Patients in control group were iv administered with Cerebroprotein Hydrolysate Injection on the basis treatment, 30 mL added in 250 mL physiological saline, once daily. Patients in treatment group were po administered with Nuodikang Capsules, 2 grains/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the efficacy was evaluated, and the scores of MMSE, ADL, PSMS, and IADLS in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 70.0% and 80.0%, respectively, and there were differences between two groups (P < 0.05). The MMSE scores in two groups were significantly reduced, and the scores of ADL, PSMS, and IADLS in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). Those observation indexes improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Nuodikang Capsules combined with Cerebroprotein Hydrolysate Injection has good effect in treatment of cognitive dysfunction after cerebral infarction, can improve the mental state of patients, and also can improve the quality of life, which has a certain clinical application value.
[中圖分類號]
[基金項目]